Drug Profile
Calcitonin oral - Bone Medical
Alternative Names: BN 002; CapsitoninLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Bone Medical
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin stimulants; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Osteoporosis; Pain
Most Recent Events
- 08 Aug 2019 Discontinued - Phase-II for Pain in Australia (PO)
- 28 Jan 2013 Phase-II clinical trials in Pain in Australia (PO)
- 20 Jul 2012 The European Medicines Agency recommended that due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .